

1 **Supplementary Figures**

2

3 **Inhibition of the signal peptidase complex blocks cleavage of HTLV-1 ORF1
4 encoded p12 to p8 and impairs virus transmission**

5

6 Florian Simon¹, Norbert Donhauser¹, Laura M. Kemeter¹, Franziska Wittdorf¹,
7 Sebastian Millen¹, Heinrich Sticht^{2, 3}, Andrea K. Thoma-Kress^{1, 3, *}









8

9 ¹ Institute of Clinical and Molecular Virology, Friedrich-Alexander-Universität
10 Erlangen-Nürnberg (FAU), Erlangen, Germany.

11 ² Institute of Biochemistry, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU),
12 Erlangen, Germany.


13 ³ FAU Profile Center Immunomedicine (FAU I-MED), Friedrich-Alexander-Universität
14 Erlangen-Nürnberg (FAU), Erlangen, Germany.

15 * corresponding author; andrea.thoma-kress@uk-erlangen.de

A**B****C****D****E****F****G****H****I**

17 **Supplementary Figure 1: Commercial protease inhibitors do not interfere with**
18 **p12 cleavage in Jurkat.**

19 **(A)** The p12 cleavage site was analysed with the MEROPS data base. **(B-I)** At 4 h prior
20 electroporation, Jurkat T-cells were treated with two concentrations of one of the
21 protease inhibitors (AEBSF: 0.01 mM, 0.1 mM; 6-Aminohexanoic acid: 0.025 mg/ml,
22 0.25 mg/ml; Antipain dihydrochloride: 1 μ M, 100 μ M; Aprotinin: 10 nM, 800 nM;
23 Benzamidine: 0.5 mM, 4 mM; Bestatin: 4 μ M, 40 μ M; Chymostatin: 10 μ M, 100 μ M;
24 E64: 1 μ M, 10 μ M; EDTA: 0.1 mM, 1 mM; NEM: 0.01 mM, 0.1 mM; Leupeptin: 10 μ M,
25 100 μ M; Pepstatin: 0.5 μ g/ml, 1 μ g/ml; Phosphoramidon: 1 μ M, 10 μ M; Trypsin: 10
26 μ g/ml, 100 μ g/ml). Next, cells were electroporated with 50 μ g HA-tagged pME-p12WT
27 or pME and treated with the respective protease inhibitor for 24 h. Cells were lysed
28 with the respective protease inhibitor added to corresponding lysis buffer and analysed
29 via **(B-G)** immunoblotting with anti-HA and anti- β -actin antibodies. **(H)** Densitometric
30 analysis of p12 and p8 specific bands was performed. p12 cleavage was calculated as
31 p8/(p12+p8) and normalized to respective solvent control. The mean of two
32 independent experiments is depicted. **(I)** Cells were stained with propidium iodide (PI).
33 Cell viability was analysed via flow cytometry and normalized to respective solvent
34 control. The mean of two independent experiments is depicted.




35

36 **Supplementary Figure 2: p12 is predicted to carry a signal peptide using PrediSi.**

37 The p12 wildtype (WT) sequence was analysed with the signal peptide prediction tool

38 PrediSi.



39

40 **Supplementary Figure 3: Inhibition of p12 cleavage does not affect HTLV-1 cell-
41 to-cell transmission from C91-PL to Jurkat.**

42 **(A-D)** Chronically HTLV-1 infected C91-PL cells were treated with DMSO or increasing
43 doses (0.2 μM, 1 μM or 2.5 μM) of either Cav or CavOH. After 48 h of treatment, cells
44 were analysed via **(A)** immunoblotting with anti-Gag, anti-Tax-1 and anti-GAPDH
45 antibodies. One representative of three independent experiments is shown. **(B)** Cell
46 viability was analysed via flow cytometry. **(C)** Cell growth was analysed via automated

47 cell counting. **(D)** Viral release was analysed via Gag-p19 ELISA. The means of three
48 independent experiments \pm SEM are depicted. **(E)** C91-PL were treated with DMSO, 1
49 μ M Cav or CavOH for 24 h before co-culture with Jurkat-IRES-zsGreen cells. After 1
50 h, cells were fixed, stained intracellularly against Gag, and analysed via flow cytometry.
51 Quantitative analysis of gag-p19-APC-positive cells normalized to DMSO control was
52 conducted. The means of three independent experiments \pm SEM are depicted. Data
53 were analysed by Kruskal-Wallis test followed by Dunn's multiple comparisons
54 correction. * $p<0.05$, ** $p<0.01$.